Physician profile
Kaelyn E Lay
NPI 1962948075
$4,079.23
in general payments reported to CMS, 2019-2025
25 companies · $1,429 in 2025
The $1,429 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $824 · 2024: $1,826 · 2025: $1,429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,079.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $851.05 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $598.57 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $526.28 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $232.64 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.53 | 2023-2025 | Jardiance, Ofev, Spiriva Respimat |
| Pfizer INC. | $225.76 | 2023-2025 | |
| Amgen INC. | $175.02 | 2023-2025 | Prolia, Evenity, Repatha |
| Idorsia Pharmaceuticals US INC | $168.75 | 2024 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $143.82 | 2023-2025 | |
| Glaxosmithkline, LLC. | $106.86 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.53 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Exact Sciences Corporation | $105.03 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $97.64 | 2024-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $93.63 | 2023-2024 | Spravato |
| Phathom Pharmaceuticals, INC. | $78.60 | 2024-2025 | Voquezna |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $70.30 | 2023-2024 | Gardasil 9, Capvaxive, Gardasil |
| Sumitomo Pharma America, INC. | $51.15 | 2023-2025 | Gemtesa |
| Eisai INC. | $44.85 | 2024-2025 | |
| Abbott Laboratories | $40.24 | 2024 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $36.04 | 2024-2025 | Rexulti |
| Ironwood Pharmaceuticals, INC | $29.60 | 2024 | |
| Sanofi-Aventis U.S. LLC | $20.84 | 2023 | |
| Novartis Pharmaceuticals Corporation | $18.97 | 2025 | |
| Dexcom, INC. | $15.77 | 2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $12.76 | 2023 | Vyepti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaelyn Lay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.